Comparative Pharmacology
Head-to-head clinical analysis: DRICORT versus HI COR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRICORT versus HI COR.
DRICORT vs HI-COR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with predominant glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell function.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
DRICORT (dexamethasone) typical adult dose: 0.5-9 mg/day orally in divided doses every 6-12 hours, or 0.5-24 mg IV/IM once or divided. Anti-inflammatory: 0.75-9 mg/day PO/IV in 2-4 divided doses. Severe conditions: up to 16 mg/day in divided doses. Short-term high-dose: up to 40-100 mg IV push for specific indications.
0.1-0.2 mg/kg intravenously once.
None Documented
None Documented
Terminal elimination half-life is 10-12 hours in adults with normal renal function, allowing twice-daily dosing.
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Primarily renal (80-85% as unchanged drug and metabolites), with 15-20% excreted in feces via biliary elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Category C
Category C
Corticosteroid
Corticosteroid